Wilson Sonsini Goodrich & Rosati advised Terray on the transaction. Terray Therapeutics (Terray), a biotechnology company, announced raising $120 million in Series B funding round. The...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Ochre Bio in the transaction. Ochre Bio, a pioneer in chronic liver disease medicine development, announced the start of a...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented client Section 32 on the deal while Wilson Sonsini advised BigHat Biosciences. Section 32, a venture capital fund that invests in frontiers of...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Recursion on the deal. Recursion, a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development,...
You must be a Standard 1 Year member to access this content.
